Trevena (NASDAQ:TRVN) Now Covered by Analysts at Wall Street Zen

Wall Street Zen assumed coverage on shares of Trevena (NASDAQ:TRVN) in a research report released on Thursday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Trevena Trading Down 2.8%

Shares of Trevena stock opened at $1.06 on Thursday. Trevena has a twelve month low of $0.95 and a twelve month high of $10.92. The stock has a market capitalization of $1.02 million, a P/E ratio of -0.02 and a beta of 0.87. The business’s fifty day moving average price is $1.22 and its 200 day moving average price is $1.53.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.